Inhibikase Therapeutics, Inc.
IKT
$1.44
$0.032.13%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -100.00% |
| Cost of Revenue | 135.24% | 125.35% | 84.77% | 26.38% | -4.75% |
| Gross Profit | -135.24% | -126.85% | -87.49% | -28.84% | 2.44% |
| SG&A Expenses | 219.64% | 163.78% | 113.47% | 69.02% | 5.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 163.08% | 137.63% | 94.41% | 40.48% | -1.38% |
| Operating Income | -163.08% | -138.62% | -96.30% | -42.31% | -0.21% |
| Income Before Tax | -143.58% | -125.79% | -90.35% | -44.62% | -2.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -143.58% | -125.79% | -90.35% | -44.62% | -2.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -143.58% | -125.79% | -90.35% | -44.62% | -2.27% |
| EBIT | -163.08% | -138.62% | -96.30% | -42.31% | -0.21% |
| EBITDA | -163.09% | -138.69% | -97.90% | -43.44% | -0.97% |
| EPS Basic | 79.26% | 61.55% | 47.30% | 33.74% | 26.00% |
| Normalized Basic EPS | 78.58% | 61.08% | 46.88% | 33.75% | 26.00% |
| EPS Diluted | 79.26% | 61.55% | 47.30% | 33.74% | 26.00% |
| Normalized Diluted EPS | 78.58% | 61.08% | 46.88% | 33.75% | 26.00% |
| Average Basic Shares Outstanding | 1,080.69% | 893.58% | 616.56% | 310.72% | 36.93% |
| Average Diluted Shares Outstanding | 1,080.69% | 893.58% | 616.56% | 310.72% | 36.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |